soul trial oral semaglutide cardiovascular outcomes nejm 2024 2025 Oral Semaglutide's Impact on Cardiovascular Events in Type 2 Diabetes Patients with Cardiovascular and Kidney Disease: SOUL Trial Results soul trial oral semaglutide cardiovascular

Only the L-isomer of carnitine is biologically active (1)

Both oral and injectable GLP-1 therapies can cause nausea, constipation, or diarrhea, particularly during dose escalation

Because the heart relies heavily on fatty acids as an energy source, efficient fatty acid transport plays an important role in maintaining normal cardiac energy metabolism

This study reported that L-carnitine supplementation effectively reduced levels of inflammatory markers and oxidative stress, and importantly, was associated with improved clinical outcomes (64)

2009;6(1-4):e31-e39

Compliant positioning beats price positioning for AI citation